BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ORION Biotech Catalyst Calendar//company//EN
CALSCALE:GREGORIAN
X-WR-CALNAME:ORION — PHAR stated timing
X-WR-CALDESC:Exact dates PHAR stated in SEC filings\, quoted as written\, w
 ith SEC links. No forecasts.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:orion-event-FDA20261030-PHAR-JOENJA-13-27KG-SNDA@orionbiotechai.com
SEQUENCE:1
DTSTAMP:20261029T000000Z
LAST-MODIFIED:20261029T000000Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:PHAR Joenja (leniolisib)\, lower-dose formulation: FDA decision\, 
 “January 30\, 2027”
DESCRIPTION:Pharming Group N.V. (PHAR)\, Joenja (leniolisib)\, lower-dose f
 ormulation: PDUFA target action date.\nCompany wording\, as written: “On
  September 28\, 2026\, we announced that the FDA had accepted this sNDA an
 d granted the application Priority Review and assigned a Prescription Drug
  User Fee Act (PDUFA) target action date of January 30\, 2027.”\nStated 
 period: “January 30\, 2027”.\nFiled 2026-10-27\, SEC Form 6-K\, EX-99.
 1.\nSEC filing: https://www.sec.gov/Archives/edgar/data/1828316/0001828316
 26000049/a2026q3pressrelease.htm\nORION page: https://www.orionbiotechai.c
 om/company/PHAR?src=ics\nORION records what the company wrote. It is not a
  forecast.
URL:https://www.orionbiotechai.com/company/PHAR?src=ics
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR